Freeline Therapeutics makes its NASDAQ debut

Freeline Therapeutics Holdings plc (“Freeline”), a UCL Technology Fund portfolio company, has made its debut on NASDAQ in the United States.

Freeline is a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases. It announced the pricing of its initial public offering in the United States of 8,823,529 American Depositary Shares (“ADSs”) representing 8,823,529 ordinary shares at an initial public offering price of $18.00 per ADS for total gross proceeds of approximately $158.8 million.

Freeline was founded in 2015, based on the research of Professor Amit Nathwani of the UCL Cancer Institute.

Read more on the Freeline website.

Related Content

We make UCL’s research physical and life sciences ideas happen.